Incyte

Blood cancer trial finds ruxolitinib better than current treatments
Blood cancer trial finds ruxolitinib better than current treatments
Clinical Trials Arena
clinical trials
polycythemia vera
Jakafi
Incyte
Flag link:
Incyte whittles down pipeline, scrapping 6 R&D programs
Incyte whittles down pipeline, scrapping 6 R&D programs
Fierce Biotech
Incyte
R7D
anemia
cancer
Flag link:
Biotech heads towards big catalysts
Biotech heads towards big catalysts
EP Vantage
biotech
clinical trials
Alnylam Pharmaceuticals
Arcus Biosciences
Argenx
Arrowhead Pharmaceuticals
Axsome Therapeutics
Bavarian Nordic
FibroGen
Gilead Sciences
Incyte
Morphic Therapeutic
PTC Therapeutics
Syndax Pharmaceuticals
Travere Therapeutics
Vaxcyte
Flag link:
Incyte hit by CRL on extended-release JAK tablets, muddying plans for Jakafi franchise expansion
Incyte hit by CRL on extended-release JAK tablets, muddying plans for Jakafi franchise expansion
Endpoints
Incyte
FDA
ruxolitinib
CRL
Flag link:
In a surprise approval, FDA green-lights Incyte's PD-1 inhibitor to treat rare cancer type
In a surprise approval, FDA green-lights Incyte's PD-1 inhibitor to treat rare cancer type
Fierce Pharma
Incyte
Zynyz
FDA
Merkel cell carcinoma
Flag link:
Incyte touts mid-stage data for new JAK inhibitor but stops short of selecting PhIII dose
Incyte touts mid-stage data for new JAK inhibitor but stops short of selecting PhIII dose
Endpoints
AAD
Incyte
JAK inhibitors
povorcitinib
vitiligo
Flag link:
Incyte reports data from Phase IIb vitiligo therapy trial
Incyte reports data from Phase IIb vitiligo therapy trial
Clinical Trials Arena
Incyte
povorcitinib
vitiligo
clinical trials
Flag link:
Incyte Abandons Phase III Trial for Myelofibrosis Treatment
Incyte Abandons Phase III Trial for Myelofibrosis Treatment
BioSpace
Incyte
clinical trials
myelofibrosis
Jakafi
Flag link:
Go or no go? Vaccines and neurology up for discussion
Go or no go? Vaccines and neurology up for discussion
EP Vantage
FDA
Acadia Pharmaceuticals
Apellis Pharmaceuticals
AstraZeneca
Biogen
Biomarin
Cidara Therapeutics
Emergent BioSolutions
GSK
Incyte
Ionis Pharmaceuticals
Melinta Therapeutics
Mundipharma
Novartis
Pfizer
Pharming
Regeneron
Roche
vaccines
RSV
ALS
COVID-19
Flag link:
Incyte reports new data from hidradenitis suppurativa therapy trial
Incyte reports new data from hidradenitis suppurativa therapy trial
Clinical Trials Arena
Incyte
clinical trials
hidradenitis suppurativa
povorcitinib
Flag link:
Insmed, Alnylam and others make Science's list of top 20 biopharma employers
Insmed, Alnylam and others make Science's list of top 20 biopharma employers
Endpoints
employers
Inbsmed
Alnylam
Regeneron
Incyte
Flag link:
SITC 2022 preview – cytokines and oral checkpoints
SITC 2022 preview – cytokines and oral checkpoints
EP Vantage
SITC
Incyte
ChemoCentryx
Amgen
cytokines
Flag link:
Incyte pays out $70M to get hands on Medicxi-backed vitiligo biotech
Incyte pays out $70M to get hands on Medicxi-backed vitiligo biotech
Endpoints
Incyte
M&A
Villaris Therapeutics
vitiligo
Medicxi
Flag link:
FDA Action Alert: Incyte, Arcutis Await Decisions in Vitiligo, Psoriasis
FDA Action Alert: Incyte, Arcutis Await Decisions in Vitiligo, Psoriasis
BioSpace
FDA
Incyte
Arcutis Biotherapeutics
Opzelura
vitiligo
roflumilast
psoriasis
Flag link:
MorphoSys Adds HIBio to Busy Collaboration Week
MorphoSys Adds HIBio to Busy Collaboration Week
BioSpace
MorphoSys
HIBio
Pfizer
Incyte
Flag link:
Opportunities arise for once-spurned partners
Opportunities arise for once-spurned partners
EP Vantage
Pfizer
Biohaven
licensing
M&A
Aurinia
Bristol Myers Squibb
AbbVie
Alector
Arcus Biosciences
Biogen
Blueprint Medicines
CureVac
Gilead Sciences
GSK
Incyte
MorphoSys
Roche
Nestle
SAGE Therapeutics
Sarepta Therapeutics
Seres Therapeutics
Syndax
Flag link:
FDA approves new indication for drug to treat severe COVID-19
FDA approves new indication for drug to treat severe COVID-19
Beckers Hospital Review
Eli Lilly
Incyte
baricitinib
FDA
olumiant
COVID-19
Flag link:
Incyte's Opzelura slapped with vitiligo delay amid topical JAK's eczema launch
Incyte's Opzelura slapped with vitiligo delay amid topical JAK's eczema launch
Fierce Pharma
Incyte
Opzelura
eczema
vitiligo
Flag link:
A new JAK inhibitor earns FDA nod in myelofibrosis, setting up a fight with Incyte, Bristol Myers
A new JAK inhibitor earns FDA nod in myelofibrosis, setting up a fight with Incyte, Bristol Myers
Endpoints
CTI BioPharma
JAK inhibitors
Vonjo
pacritinib
FDA
myelofibrosis
Incyte
Bristol Myers Squibb
Flag link:
Novartis JAKs in rival to Incyte's topical eczema drug after seeing clinical data
Novartis JAKs in rival to Incyte's topical eczema drug after seeing clinical data
Fierce Biotech
Novartis
Incyte
JAK inhibitors
Opzelua
eczema
atopic dermatitis
Flag link:

Pages